## 502493959 09/12/2013

## PATENT ASSIGNMENT

Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

# **CONVEYING PARTY DATA**

Name	Execution Date
Bend Research, Inc.	08/10/2004

#### RECEIVING PARTY DATA

Name:	Pfizer Inc.
Street Address:	235 East 42nd St.
City:	New York
State/Country:	NEW YORK
Postal Code:	10017

#### PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	10596876

#### CORRESPONDENCE DATA

Fax Number: 5035955301

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 503-595-5300

Email: deborah.martin@klarquist.com

Correspondent Name: Lisa M. Caldwell, Klarquist Sparkman LLP

Address Line 1: 121 SW Salmon Street

Address Line 2: One World Trade Center, Suite 1600
Address Line 4: Portland, OREGON 97204-2988

ATTORNEY DOCKET NUMBER:	8191-91767-01 PC32026
NAME OF SUBMITTER:	Lisa M. Caldwell
Signature:	/Lisa M. Caldwell/
Date:	09/12/2013

#### Total Attachments: 2

source=Assignment (BRI to PI)#page1.tif source=Assignment (BRI to PI)#page2.tif

PATENT REEL: 031197 FRAME: 0586

Patent Application Docket No. PC32026

Bend To Pfizer (Whole Interest) Provisional

### **ASSIGNMENT**

WHEREAS, Bend Research, Inc., an Oregon corporation, having a business address at 64550 Research Road, Bend, Oregon, is the owner of an interest in an invention for which the patent application hereinafter identified has been filed.

NOW, THEREFORE, for valuable consideration, the receipt and adequacy of which is hereby acknowledged, Bend Research, Inc. does hereby sell, assign and transfer unto PFIZER INC., a Delaware corporation having a principal place of business at 253 East 42<sup>nd</sup> Street, New York, New York 10017, its entire right, title and interest in and to the provisional patent application of the United States of America having a U. S. filing date of December 31, 2003, having PFIZER INC. Docket No. PC32026 having U. S. provisional application number 60/533,836, and entitled SOLID COMPOSITIONS OF LOW SOLUBILITY DRUGS AND POLOXAMERS; and its entire right, title and interest, in the United States of America and in all other countries of the world, in and to all its inventions, whether joint or sole, disclosed in said provisional patent application; and any letters patent to be issued therefore in the United States or any foreign country and any divisions, continuations, continuations-in-part, improvements, reissues, reexaminations, or extensions that may be made or granted thereon; and the right to claim priority from said provisional patent application under the Paris Convention for the Protection of Industrial Property, and under any and all other such treaties and agreements to which the United States of America is a party and which afford priorityclaiming privileges, in all countries of the world including the United States of America; and Bend Research, Inc. hereby agrees, whenever requested, to

communicate to said PFIZER INC., and its successors and assigns, any facts known to it respecting said inventions, to testify in any legal proceeding respecting said inventions, and to

> PATENT **REEL: 031197 FRAME: 0587**

Patent Application Docket No. PC32026

execute all applications or papers necessary to obtain, maintain and enforce patent protection on said inventions in all countries of the world.

Dated: August 10, 2004.

Bend Research, Inc.

President, Bend Research, Inc.

In the presence of:

(Witness)

(Typed or Printed Name of Witness)

PATENT REEL: 031197 FRAME: 0588

**RECORDED: 09/12/2013**